参考文献/References:
［1］乙型肝炎病毒感染女性生育管理专家委员会．乙型肝炎病毒感染女性生育管理专家共识 ［J］．中华实验和临床感染病杂志（电子版），2014，8（1）：104-107．
［2］OTT J J, STEVENS G A, WIERSMA S T. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions ［J］. BMC Infectious Diseases, 2012, 12 (1): 131.
［3］蒲杰．预防艾滋病、梅毒和乙肝母婴传播技术与进展 ［M］．成都：四川科技出版社，2015：84-89．
［4］PARK J S, PAN C. Current recommendations of managing HBV infection in preconception or pregnancy ［J］. Frontiers of Medicine, 2014, 8 (2): 158-165.
［5］中华医学会妇产科学分会产科学组．乙型肝炎病毒母婴传播预防临床指南(第1版) ［J］．中华围产医学杂志，2015，18（5）：321-325．
［6］Dionne-Odom J, Tita AT, Silverman NS. Society for Maternal-Fetal Medicine (SMFM) Consult Series 38: Hepatitis B in Pregnancy- Screening, Treatment and Prevention of Vertical Transmission ［J］. Am J Obstet Gynecol, 2016,214(1):6-4.
［7］ZOU H, CHEN Y, DUAN Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers ［J］. Journal of Viral Hepatitis, 2012, 19 (2): e 18-e 25.
［8］YIN Y, STEVENS G A, GROEGER J, et al. Immunoprophylaxis of hepatitis B virus infection and its sequelae ［J］. The Journal of Infection, 2013, 66 (5): 447-452.
［9］HAN G R, CAO Min-kai, ZHAO Wei, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection ［J］. Journal of Hepatology, 2011, 55 (6): 1215-1221.
［10］慢性乙型肝炎特殊患者抗病毒治疗专家委员会．慢性乙型肝炎特殊患者抗病毒治疗专家共识：2015年更新 ［J］．中国肝脏病杂志(电子版)，2015，7（1）：115-122．
［11］中华医学会肝病学分会．中华医学会感染病学分会.慢性乙型肝炎防治指南 ［J］．中国肝脏病杂志(电子版)，2015，7（3）：1-18．
［12］TRAN T. Hepatitis B:treatment to prevent perinatal transmission ［J］. Clinical Obs Gyn, 2012, 55 (2): 541–549.
［13］DIONNE-ODOM J, TITA A T, SILVERMAN N S, et al. Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission ［J］. American Journal of Obstetrics and Gynecology, 2016, 214 (1): 6-14.
［14］VISVANATHAN K, DUSHEIKO G, GILES M, et al. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders ［J］. Gut, 2016, 65 (2): 340-350.
［15］YU Min-min, JIANG Qian, JI Ying, et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus ［J］. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 2014, 61 (1): 55-60.
［16］LOK A S, MCMAHON B J, BROWN J， et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis ［J］. Hepatology, 2016, 63 (1): 284-306.
［17］SARIN S K, KUMAR M, LAU G K, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update ［J］. Hepatology International, 2016, 10 (1): 1-98.
［18］European Association For The Study Of The Liver. EASL clinical practice guidellines:management of chronic hepatitis B ［J］. Journal of Hepatology, 2012, 57 (1): 167-185.
［19］TERRAULT N A, BZOWEJ N H, CHANG K M, et al. AASLD guidelines for treatment of chronic hepatitis B ［J］. Hepatology (Baltimore, Md.), 2016, 63 (1): 261-283.
相似文献/References:
[1]陶涛,钟兴明,高建群,等.广州市乙型肝炎病毒母婴传播阻断实施3年分析[J].中国计划生育和妇产科,2013,(03):0.
TAO Tao,ZHONG Xing - ming *,GAO Jian - qun,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(9):0.
[2]王芳,资捷*,刘泽滨,等.RIG-I配体poly(dAT:dAT)诱导Bewo细胞抑制乙型肝炎病毒复制的研究[J].中国计划生育和妇产科,2017,(11):58.
WANG Fang,ZI Jie*,LIU Ze-bin,et al.Study of RIG-I ligand poly(dAT:dAT)-induced inhibition hepatitis B virus replication in Bewo cells[J].Chinese Journal of Family Planning & Gynecotokology,2017,(9):58.
[3]王菲菲,马小星*.乙肝表面抗原和乙肝e抗原均阳性产妇乙肝病毒宫内感染情况及与Toll样受体4和干扰素-γ的相关性分析[J].中国计划生育和妇产科,2018,(10):78.
WANG Fei-fei,MA Xiao-xing*.HBV intrauterine infection in HBsAg and HBeAg positive women and its correlation with TLR4 and interferon-γ[J].Chinese Journal of Family Planning & Gynecotokology,2018,(9):78.